Tysabri continues to prop up Elan with 18% revenue jump
This article was originally published in Scrip
Executive Summary
Irish pharma company Elan reported a 5% increase in total revenue to $1.17 billion for 2010 driven by increased revenue from Tysabri (natalizumab). Elan's portion of sales from the multiple sclerosis (MS) treatment, which is co-marketed with Biogen Idec, increased by 18% to $851.5 million for the full year.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.